Intended for UK Healthcare professionals.
The prescribing information and adverse event reporting statement are found at the bottom of this page.

Administration

Administration

Administration

How to administer Epistatus®

Epistatus® should be used exactly as directed by the doctor or epilepsy nurse. If the instructions on this page are different from what is written in the care plan, always follow the care plan instructions. Epistatus® is for oromucosal (“buccal”) use only, and must only be used in the mouth. It should be administered directly from the pre-filled buccal syringe into the patient’s buccal cavity (the space between the inner cheek and the gums):1-4

As soon as the person’s seizure starts, make a note of the time.

Place something soft under the head for protection and support. Locate the person’s Epistatus® and continue timing the seizure. If it goes on for 5 minutes or more, Epistatus® should be administered.

Check the medication for the expiry date, and do not use if the solution is not clear (e.g. cloudy or white particles present).

Unscrew the amber cap/sheath.

Pull back the cheek and insert into the space between the cheek and teeth (buccal cavity). Do not put in between teeth.

Administer medicine slowly, 2-3 seconds in each cheek, or just into one over 4-5 seconds if difficulty in accessing one buccal cavity.

Dispose of the syringe and cap safely.
Put the person into the recovery
position once the
seizure has finished.

Note the time. If the person’s seizure doesn’t stop within 5 minutes of giving Epistatus®, call an ambulance.

Record what happened in the person’s care plan.

How to administer

After receiving Epistatus®, patients should be kept under supervision by a carer. If the seizure does not stop shortly after administration or the condition improves but the seizure starts again, call an ambulance, taking into account instructions from the care plan and their doctor.

A second dose of Epistatus® should not be given without medical advice.

This video is also available for patients and carers to access directly via the Epistatus® patient website, accessible here. This website has been produced by Veriton Pharma as an educational resource for patients / carers who have been prescribed Epistatus. To email your patient a copy of the Patient Website’s URL and, please click here.

To download the video, please use the settings in the video above (please be aware, this could take up to 10-15 minutes to download).

References:

  1. Epistatus® 2.5 mg Oromucosal Solution Summary of Product Characteristics (SmPC).
  2. Epistatus® 5 mg Oromucosal Solution SmPC. 
  3. Epistatus® 7.5 mg Oromucosal Solution SmPC. 
  4. Epistatus® 10 mg Oromucosal Solution SmPC. 

EDM-1007y-2022

Date of Last Revision: April 2024

Demonstration video

The following video can be used as a training aid for both healthcare professionals and patients / carers. It demonstrates how to locate the buccal cavity and administer Epistatus®.

This video is also available for patients / carers to access directly via the Epistatus® patient website, accessible here. This website has been produced by Veriton Pharma as an educational resource for patients who have been prescribed Epistatus®. To email your patient a copy of the Patient Website’s URL, please click here. To download the video, please use the settings in the video above (please be aware, this could take up to 10-15 minutes to download).

EDM-1007z-2022

Date of Last Revision: April 2024

Printable materials and patient website

Patient leaflet including ‘how to administer’ information

This leaflet is available as a reference to help your patients and carers understand how to administer Epistatus®:

A printable version of the leaflet is available here.

If you would like a hard-copy supply of Epistatus® patient support materials, please contact your Veriton Pharma medical representative by clicking here or by calling +44 (0)1932 690325.

Epistatus® patient website

The Epistatus® patient website contains useful patient resources, including general information about epilepsy along with reference information and training materials that are specific to Epistatus®. There is also a special section for children with a younger reading age. Please note that due to the presence of product-specific information, this website is only suitable for patients who currently have a prescription for Epistatus®. This website is produced and provided as an educational resource for patients and carers by Veriton Pharma, and is accessible here. To email your patient a copy of the Patient Website’s URL please click here.

EDM-1007aa-2022

Date of Last Revision: June 2024

Seizures:
The Facts
About Epistatus®

Access

Resources